Authors
K Galaal, J Vickery, A Lopes, C Pritchard, A Barton, J Wingham, EM Elsa Marques, J Palmer, C Ralph, J Fauld, P Ewings
Publication date
2019/11/1
Journal
International Journal of Gynecological Cancer
Volume
29
Issue
Suppl 4
Pages
A33-A33
Publisher
BMJ Publishing Group Ltd
Description
Results
173 women were approached, and 59 took part. In the ICS group, 16 (62%) of the 26 participants received ICS reinfusion. In the donor blood group, 14 of the 29 (48%) received donor blood. Twenty-two (40%) participants (9 ICS, 13 control) experienced infections, mainly wound, urinary tract or chest. Six participants died (2 ICS, 4 control) were all due to disease progression.
Conclusion
We have demonstrated that ICS is safe and acceptable alternative to blood transfusion in ovarian cancer surgery. Further larger randomised trial is needed to determine the long term outcomes.
Total citations
20231
Scholar articles
K Galaal, J Vickery, A Lopes, C Pritchard, A Barton… - International Journal of Gynecological Cancer, 2019